Related references
Note: Only part of the references are listed.Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion
Malte Lenders et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study
Maarten Arends et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease
M. Lenders et al.
JOURNAL OF INTERNAL MEDICINE (2017)
Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes
Albina Nowak et al.
MOLECULAR GENETICS AND METABOLISM (2017)
Anti-BlyS antibody reduces the immune reaction against enzyme and enhances the efficacy of enzyme replacement therapy in Fabry disease model mice
Yohei Sato et al.
CLINICAL IMMUNOLOGY (2017)
X-chromosome inactivation in female patients with Fabry disease
L. Echevarria et al.
CLINICAL GENETICS (2016)
Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease
Malte Lenders et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction
Priya S. Kishnani et al.
MOLECULAR GENETICS AND METABOLISM (2016)
Genotype: A Crucial but Not Unique Factor Affecting the Clinical Phenotypes in Fabry Disease
Xiaoxia Pan et al.
PLOS ONE (2016)
Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
Michael Beck et al.
MOLECULAR GENETICS AND METABOLISM REPORTS (2015)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications
F. Weidemann et al.
JOURNAL OF INTERNAL MEDICINE (2013)
Anti-α-galactosidase A antibody response to agalsidase beta treatment: Data from the Fabry Registry
William R. Wilcox et al.
MOLECULAR GENETICS AND METABOLISM (2012)
Globotriaosylsphingosine Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease
Mehdi Namdar et al.
PLOS ONE (2012)
Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome
Saskia M. Rombach et al.
PLOS ONE (2012)
Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy
Maria D. Sanchez-Nino et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2011)
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
Raphael Schiffmann et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Sustained, long-term renal stabilization after 54 months of agalsidase β therapy in patients with Fabry disease
Dominique P. Germain et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
High incidence of later-onset Fabry disease revealed by newborn screening
Marco Spada et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting
R Schiffmann et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2006)
Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta
GE Linthorst et al.
KIDNEY INTERNATIONAL (2004)
Share Paper
